Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus

Candis M Morello, Candis M Morello

Abstract

Introduction: The goal of insulin therapy in patients with either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) is to match as closely as possible normal physiologic insulin secretion to control fasting and postprandial plasma glucose. Modifications of the insulin molecule have resulted in two long-acting insulin analogs (glargine and detemir) and three rapid-acting insulins (aspart, lispro, and glulisine) with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles. These agents can be used together in basal-bolus therapy to more closely mimic physiologic insulin secretion patterns.

Methods: This study reviews effects of the multiple demographic and clinical parameters in the insulin analogs glargine, detemir, lispro, aspart, and glulisine in patients with T2DM. A search was conducted on PubMed for each major topic considered (effects of injection site, age, race/ethnicity, obesity, renal or hepatic dysfunction, pregnancy, exercise, drug interactions) using the topic words and name of each type of insulin analog. Information was also obtained from the prescribing information for each insulin analog.

Results: The PK/PD profiles for insulin analogs may be influenced by many variables including age, weight, and hepatic and renal function. However, these variables do not have equivalent effects on all long-acting or rapid-acting insulin analogs.

Conclusion: Rapid-acting and long-acting insulin analogs represent major advances in treatment for patients with T2DM who require insulin therapy. However, there are potentially important PK and PD differences between the two long-acting agents and among the three rapid-acting insulin analogs, which should be considered when designing treatment regimens for special patient groups.

Keywords: insulin analogs; pharmacodynamics; pharmacokinetics; type 2 diabetes mellitus.

Figures

Figure 1
Figure 1
Mean 24-hour physiologic serum insulin and plasma glucose levels in nondiabetic subjects. Reprinted from Am J Med, vol. 113, issue 4, Gerich, Novel insulins: expanding options in diabetes management, pp. 308–316, Copyright (2002), with permission from Elsevier.
Figure 2
Figure 2
The regulation of metabolism by insulin. Reprinted from Nature, vol. 414, issue 6865, Saltiel and Kahn, Insulin signalling and the regulation of glucose and lipid metabolism, pp. 799–806, Copyright (2001), with permission from Nature Publishing Group. Abbreviation: FFA, free fatty acids.

References

    1. Bogardus C, Tataranni PA. Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians. Diabetes. 2002;51(Suppl 1):S262–S264.
    1. King AB, Armstrong DU. Basal bolus dosing: a clinical experience. Curr Diabetes Rev. 2005;1:215–220.
    1. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med. 2002;113:308–316.
    1. Levemir® (insulin detemir [rDNA origin] injection) [prescribing information] Princeton, NJ: Novo Nordisk Inc; 2010.
    1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799–806.
    1. Kahn SE, Montgomery B, Howell W, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2001;86:5824–5829.
    1. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Medeau V, Kevorkian JP. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab. 2008;34(Suppl 2):S43–S48.
    1. Burcelin R, Knauf C, Cani PD. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metabolism. 2008;34(Suppl 2):S49–S55.
    1. Campbell RK, White JR., Jr Insulin therapy in type 2 diabetes. J Am Pharm Assoc (Wash) 2002;42:602–611.
    1. Eliasson B, Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjornsdottir S. Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. Diabetes Metab. 2007;33:269–276.
    1. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther. 2011;13(Suppl 1):S5–S14.
    1. Schmid H. New options in insulin therapy. J Pediatria (Rio J) 2007;83(Suppl 5):S146–S155.
    1. Becker RHA, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes. 2005;113:435–443.
    1. Osterberg O, Erichsen L, Ingwersen SH, Plum A, Poulsen HE, Vicini P. Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J Pharmacokinet Pharmacodyn. 2003;30:221–235.
    1. Levy P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. Med Gen Med. 2007;9:12.
    1. Novolin® R [prescribing information] Princeton, NJ: Novo Nordisk Inc; May 14, 2010.
    1. Novolin® N [prescribing information] Princeton, NJ: Novo Nordisk Inc; May 14, 2010.
    1. Walsh JA, Roberts R, Bailey T, Varma CB. Using Insulin: Everything You Need for Success With Insulin. San Diego, CA: Torrey Pines Press; 2003.
    1. Humalog® (insulin lispro [rDNA origin] injection) [prescribing information] Indianapolis, IN: Eli Lilly and Company; May 18, 2011.
    1. NovoLog® (insulin aspart [rDNA origin] injection) [prescribing information] Princeton, NJ: Novo Nordisk Inc; Jul, 2011.
    1. Apidra® (insulin glulisine) [prescribing information] Bridgewater, NJ: Sanofi-Aventis; 2009.
    1. Helms KL, Kelley KW. Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application. Ann Pharmacother. 2009;43:658–668.
    1. Lantus® (insulin glargine [rDNA origin] injection) [prescribing information] Bridgewater, NJ: Sanofi-Aventis; Mar 2, 2007.
    1. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107–1112.
    1. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough – what next? Diabetes Metab Res Rev. 2007;23:257–264.
    1. Garber AJ, Clauson P, Pedersen CB, Kolendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc. 2007;55:1735–1740.
    1. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086.
    1. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622–629.
    1. Hompesch M, Ocheltree SM, Wondmagegnehu ET, et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin. 2009;25:2679–2687.
    1. King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab. 2009;11:69–71.
    1. Pscherer S, Dietrich ES, Dippel FW, Neilson AR. Comparison of one- year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. Int J Clin Pharmacol Ther. 2010;48:129–137.
    1. Barnett AH. How well do rapid-acting insulins work in obese individuals? Diabetes Obes Metab. 2006;8:388–395.
    1. Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Clin Pharmacokinet. 2008;47:595–610.
    1. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008;47:7–20.
    1. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–559.
    1. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet. 2001;40:641–659.
    1. Wutte A, Plank J, Bodenlenz M, et al. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007;115:461–467.
    1. Wang Z, Hedrington MS, Gogitidze JN, et al. Dose response effects of insulin glargine in type 2 diabetes. Diabetes Care. 2010;33:1555–1560.
    1. Gin H, Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab. 2005;31:7–13.
    1. EMEA. Scientific discussion of insulin detemir. 2004. [Accessed November 16, 2011]. Available at: .
    1. Injection site selection. [Accessed November 10, 2011]. Available at: .
    1. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 aspinsulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22:1501–1506.
    1. ter Braak EW, Woodworth JR, Bianchi R, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care. 1996;19:1437–1440.
    1. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17:571–584.
    1. Krones R, Schutte C, Heise T. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab. 2009;11:41–44.
    1. Hompesch M, Troupin B, Heise T, et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab. 2006;8:568–573.
    1. Rave K, Nosek L, Heinemann L, Frick A, Becker R. Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. Diabetes Metab. 2003;29:430–431.
    1. Kaku K, Matsuda M, Urae A, Irie S. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract. 2000;49:119–126.
    1. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61:737–747.
    1. Crawford AG, Cote C, Couto J, et al. Prevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE centricity electronic medical record database. Popul Health Manag. 2010;13:151–161.
    1. Fernandez-Veledo S, Nieto-Vazquez I, Vila-Bedmar R, Garcia- Guerra L, Alonso-Chamorro M, Lorenzo M. Molecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach. Arch Physiol Biochem. 2009;115:227–239.
    1. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60:469–476.
    1. Craig KJ, Donovan K, Munnery M, Owens DR, Williams JD, Phillips AO. Identification and management of diabetic nephropathy in the diabetes clinic. Diabetes Care. 2003;26:1806–1811.
    1. Rave K, Heise T, Pfutzner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24:886–890.
    1. Shrishrimal K, Hart P, Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med. 2009;76:649–655.
    1. Home PD, Pacini G. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes Obes Metab. 2008;10:699–718.
    1. Gray RS, Cowan P, Steel JM, Johnstone FD, Clarke BF, Duncan LJ. Insulin action and pharmacokinetics in insulin treated diabetics during the third trimester of pregnancy. Diabetes Metab. 1984;1:273–278.
    1. Klieger C, Pollex E, Kazmin A, Koren G. Hypoglycemics: pharmacokinetic considerations during pregnancy. Ther Drug Monit. 2009;31:533–541.
    1. Guerci B, Sauvanet JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab. 2005;31:4S7–4S24.
    1. Peter R, Luzio SD, Dunseath G, et al. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2005;28:560–565.
    1. Rabasa-Lhoret R, Bourque J, Ducros F, Chiasson JL. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro) Diabetes Care. 2001;24:625–630.
    1. EDIC Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care. 1999;22:99–111.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren